Fang H, Yao B, Yan Y, et al. Diabetes mellitus increases the risk of bladder cancer: an updated meta-analysis of observational studies. Diabetes Technol Ther. 2013;15(11):914-22. https://pubmed.ncbi.nlm.nih.gov/24180357 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817892 https://doi.org/10.1089/dia.2013.0131

Currie CJ, Poole CD, Gale EAM. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52(1):1766–77. https://pubmed.ncbi.nlm.nih.gov/19572116 https://doi.org/10.1007/s00125-009-1440-6

Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009;32(1):1620–5. https://pubmed.ncbi.nlm.nih.gov/19564453 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732153 https://doi.org/10.2337/dc08-2175

Torrisi R, Mezzetti M, Johansson H, Barreca A, Pigatto F, Robertson C, Decensi A. Time course of fenretinide-induced modulation of circulating insulin-like growth factor (IGF)-I, IGF-II and IGFBP-3 in a bladder cancer chemoprevention trial. Int J Cancer. 2000;87(1):601–5. https://pubmed.ncbi.nlm.nih.gov/10918204 https://doi.org/10.1002/1097-0215(20000815)87:4<601::aid-ijc22>3.0.co;2-w

Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009; 9(1):798–809. https://pubmed.ncbi.nlm.nih.gov/19851315 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856025 https://doi.org/10.1038/nrc2734

World Health Organization. Regional Office for the Western Pacific. The Asia-Pacific perspective: redefining obesity and its treatment. Sydney: Health Communications Australia; 2000. https://iris.who.int/bitstream/handle/10665/206936/0957708211_eng.pdf.

Accessed on May 18, 2024.

Idaiani S, Jovina TA., Mogsa DF., Pancaharjono W. Obesity and the risk of breast tumors in Indonesian women based on clinical breast examination. Thai J Pub Heath. 2020; 50(2): 161-75.

Wulandari GP, Kristina SA. Cancers attributable to obesity in Indonesia: a prevalence based study using disability adjusted life years. Glob J Health Sci. 2018; 10(8): 21-7. https://doi.org/10.5539/gjhs.v10n8p21

Solikhah S, Perwitasari D, Permatasari TAE, Safitri RA. Diet, obesity, and sedentary lifestyle as risk factor of breast cancer among women at Yogyakarta province in Indonesia. Open Access Maced J Med Sci. 2022;10(E):398–405. https://doi.org/10.3889/oamjms.2022.7228.

Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologist and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patient with obesity. Endocr Pract. 2016;22(Suppl 3):1-203. https://pubmed.ncbi.nlm.nih.gov/27219496 https://doi.org/10.4158/EP161365.GL

Iacobini C, Pugliese G, Fantauzzi CB, Federici M, Menini S. Metabolically healthy versus metabolically unhealthy obesity. Metabolism. 2019;92:51-60. https://pubmed.ncbi.nlm.nih.gov/30458177 https://doi.org/10.1016/j.metabol.2018.11.009

Lin CJ, Chang YC, Cheng TY, Lo K, Liu SJ, Yeh TL. The association between metabolically healthy obesity and risk of cancer: a systematic review and meta-analysis of prospective cohort studies. Obesity Rev. 2020;21(10):e13049. https://pubmed.ncbi.nlm.nih.gov/32476278 https://doi.org/10.1111/obr.13049

Zheng X, Peng R, Xu H, et al. The association between metabolic status and risk of cancer among patients with obesity: metabolically healthy obesity vs. metabolically unhealthy obesity. Front Nutr. 2022;25(9):783660. https://pubmed.ncbi.nlm.nih.gov/35284439 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914254 https://doi.org/10.3389/fnut.2022.783660